Intervention

Niraparib

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 41 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials41
Recruiting4
Common conditions25
Lead sponsors shown15
Advertisement

Clinical trials

41 shown
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLCNCT05718323 · 2023-12-20
RECRUITING
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerNCT05601440 · 2023-06-13
RECRUITING
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate CancerNCT04947254 · 2021-08-05
RECRUITING
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyNCT04641247 · 2021-04-16
RECRUITING
SMMART Adaptive Clinical Treatment (ACT) TrialNCT05238831 · 2023-01-30
WITHDRAWN
Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination DeficiencyNCT05461690 · 2022-09-01
UNKNOWN
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung CancerNCT05162196 · 2022-06-01
UNKNOWN
PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations CarriersNCT05232006 · 2022-05-01
NOT_YET_RECRUITING
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated TumorsNCT05169437 · 2022-03-15
TERMINATED
A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast CancerNCT05261269 · 2022-02-02
COMPLETED
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal CancerNCT04673448 · 2021-10-18
ACTIVE_NOT_RECRUITING
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid TumorsNCT04991480 · 2021-09-13
COMPLETED
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast CancerNCT04837209 · 2021-07-21
ACTIVE_NOT_RECRUITING
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular DiseaseNCT04915755 · 2021-06-28
ACTIVE_NOT_RECRUITING
Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid TumorsNCT04764084 · 2021-04-01
UNKNOWN
LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast CancerNCT04762901 · 2021-04-01
WITHDRAWN
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine CarcinomasNCT04701307 · 2021-02-01
ACTIVE_NOT_RECRUITING
Niraparib + Dostarlimab In BRCA Mutated Breast CancerNCT04584255 · 2021-01-21
ACTIVE_NOT_RECRUITING
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate CancerNCT04592237 · 2020-12-29
ACTIVE_NOT_RECRUITING
Study of M4344 in Combination With NiraparibNCT04655183 · 2020-12-01
WITHDRAWN
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate CancerNCT04577833 · 2020-11-13
ACTIVE_NOT_RECRUITING
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate CancerNCT04194554 · 2020-11-06
ACTIVE_NOT_RECRUITING
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung CancerNCT04475939 · 2020-10-26
COMPLETED
Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)NCT04240106 · 2020-06-15
COMPLETED
ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian CancerNCT04267939 · 2020-02-26
TERMINATED
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response DefectsNCT04030559 · 2020-02-25
TERMINATED
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of RecurringNCT04037254 · 2019-10-08
COMPLETED
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast CancerNCT03368729 · 2019-09-06
ACTIVE_NOT_RECRUITING
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer PatientsNCT03945721 · 2019-07-11
ACTIVE_NOT_RECRUITING
Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung CancerNCT03891615 · 2019-06-06
TERMINATED
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line ChemotherapyNCT03830918 · 2019-03-06
ACTIVE_NOT_RECRUITING
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate CancerNCT03748641 · 2019-01-25
ACTIVE_NOT_RECRUITING
A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer PatientsNCT02826512 · 2018-05-15
TERMINATED
Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast CancerNCT03329937 · 2018-04-12
COMPLETED
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042NCT03307785 · 2017-10-12
COMPLETED
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer ParticipantsNCT03308942 · 2017-09-29
COMPLETED
Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)NCT03076203 · 2017-09-22
COMPLETED
PEN-866 in Patients With Advanced Solid MalignanciesNCT03221400 · 2017-08-29
UNKNOWN
A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)NCT02924766 · 2016-10-03
COMPLETED
An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair AnomaliesNCT02854436 · 2016-08-31
COMPLETED
Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)NCT02500901 · 2016-03-01
TERMINATED

Common conditions

Breast Cancer8Advanced Cancer3Metastatic Cancer3Neoplasms3Prostatic Neoplasms3Solid Tumor3Triple Negative Breast Cancer3Advanced Malignant Solid Neoplasm2Anatomic Stage III Breast Cancer AJCC v82Anatomic Stage IV Breast Cancer AJCC v82Gastric Adenocarcinoma2HER2-negative Breast Cancer2Neoplasms, Breast2Pancreatic Cancer2Prostate Carcinoma2Stage IIC Prostate Cancer AJCC v82Stage III Lung Cancer AJCC v82Stage III Ovarian Cancer AJCC v82Stage III Pancreatic Cancer AJCC v82Stage III Prostate Cancer AJCC v82Stage IIIA Lung Cancer AJCC v82Stage IIIA Prostate Cancer AJCC v82Stage IIIB Lung Cancer AJCC v82Stage IIIB Prostate Cancer AJCC v82Stage IIIC Lung Cancer AJCC v82

Trial status mix

ACTIVE_NOT_RECRUITING12
COMPLETED11
TERMINATED6
RECRUITING4
UNKNOWN4
WITHDRAWN3
NOT_YET_RECRUITING1

Phase mix

PHASE223
PHASE120
PHASE33
EARLY_PHASE11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.